Johnson & Johnson (JNJ -0.6%) unit Janssen Biotech commits to upfront and prospective...

|About: Johnson & Johnson (JNJ)|By:, SA News Editor

Johnson & Johnson (JNJ -0.6%) unit Janssen Biotech commits to upfront and prospective milestone payments to California-based Second Genome in connection with a collaborative venture aimed at finding new treatments for ulcerative colitis.